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Polycystic ovary syndrome (PCOS) is a very heterogeneous
disease of which the exact pathophysiological mechanisms
remain unknown. In PCOS, serum anti-Müllerian hormone
(AMH) levels are significantly increased. AMH is a member of
the transforming growth factor b family and is expressed by
growing follicles in the ovaries. In PCOS, the transcriptional
regulation of AMH and AMHR2 is altered, increasing and
prolonging its temporal expression pattern. Moreover, the
recently discovered extragonadal effects of AMH suggest that
there might be a crosstalk between the ovary–placenta–brain.
This review summarizes the recent findings concerning AMH
and its role in the etiology of PCOS.
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Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder in females of reproductive age with a
prevalence of 10e15% worldwide [1,2]. It is diagnosed
by the presence of at least two of the following three
criteria: (1) oligo/amenorrhea, (2) hyperandrogenism,
and (3) polycystic ovary morphology (PCOM) [3].
Consequently, four different phenotypes can be recog-
nized, making PCOS a very heterogeneous disease.
Genetic predisposition and environmental exposure are
thought to play a major role in the pathophysiology of
PCOS [4,5]. Yet, the exact pathophysiological mecha-
nisms remain to be unraveled.www.sciencedirect.com CuIn the past years, several studies have implicated anti-
Mu¨llerian hormone (AMH) in the pathophysiology of
PCOS. AMH is a member of the transforming growth
factor b family [6] and is expressed by preantral and
small antral follicles in the ovaries [7]. AMH levels
strongly correlate with the number of antral follicles,
and in PCOS, this is reflected by significantly increased
serum AMH levels compared to normoovulatory women
[8e10]. It has therefore been suggested that AMH
levels may replace the diagnostic criteria (PCOM) in
the diagnosis of PCOS. However, a recent paper by
Teede et al. [11] reviewing this suggestion, concluded
that there is currently a lack of well-defined PCOS and
control populations and a gap in assay standardization
preventing establishment of clear cut off values.
Although it is currently premature to use serum AMH
levels as a diagnostic criterion for PCOS, accumulating
data implicate a causal role for ovarian AMH function in
all three PCOS diagnostic criteria. Moreover, the
recently discovered extragonadal effects of AMH sug-
gest that the contribution of AMH to the pathophysi-
ology of PCOS might be even more elaborate than once
thought. In this review, we will discuss these recent
insights.AMH and its role in ovarian function in
PCOS
The ovary is the most well-studied tissue regarding
AMH expression and function. The ovarian AMH
expression is detected in granulosa cells of activated
primordial follicles and is highest in preantral and small
antral follicles. AMH expression is absent in follicular
stages following follicle-stimulating hormone (FSH)e
dependent selection, although some expression remains
in cumulus cells of preovulatory follicles [12]. Expres-
sion of the AMH-specific type II receptor (AMHR2)
coincides with AMH expression, albeit that AMHR2
expression is also detected in theca cells [12]. Thus,
AMH may affect both granulosa and theca cell function.
Studies using AMH knockout (AMHKO) mouse models
revealed that AMH inhibits the primordial follicle
recruitment and selection of follicles for dominance, two
major steps in folliculogenesis. In the absence of AMH,
more primordial follicles are recruited and FSH sensi-
tivity was increased [12,13]. Furthermore, studies in the
AMHKO mice suggest that AMH may act as an intra-
ovarian inhibitor of follicular atresia [14]. The effect of
AMH on selection of follicles for dominance seems
consistent across species. However, species differencesrrent Opinion in Endocrine and Metabolic Research 2020, 12:91–97
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nonhuman primates, Xu et al. [15] showed that in vitro
treatment of macaque secondary follicles with AMH
during the first 3 weeks of culture advanced follicle
antrum formation with a week, whereas treatment with
an AMH neutralizing antibody delayed this. Consistent
with the increased growth, estradiol (E2) production of
these secondary follicles was also increased [16]. In
contrast, in mice, AMH mostly acts as a survival factor
for small preantral follicles [14]. Importantly, blocking
AMH action in vivo through intraovarian infusion of an
AMH neutralizing antibody for 4 days resulted in the
growth of multiple antral follicles in most animals [15].
In both the in vitro and in vivo experiments, blocking
AMH action in antral follicles increased E2 levels [15].
These findings suggest that AMH may have a follicle
stage-dependent effect on E2 production. Several
studies have shown that AMH reduces FSH-induced
aromatase (Cyp19a1) expression and E2 production in
human antral follicles, and that in follicular fluid, an
inverse relationship between AMH and E2 concentra-
tions exists [17e19]. Hence, it is suggested that AMH
in humans acts as a gatekeeper of follicle growth by
preventing premature selection and E2 production of
small antral follicles. Species differences in FSH-
dependency of preantral follicles may explain the
observed differences in AMH effects on follicular
growth. Although cultured macaque preantral follicles
require FSH for survival [15,20], cultured mouse folli-
cles are FSH-independent at this stage [21]. These
species differences should be taken into consideration
when translating results to human, particularly when
implicating AMH in the pathophysiology of PCOS.
In PCOS, where AMH levels are increased, the AMH
effects on follicular growth/survival and FSH sensitivity
may be exacerbated leading to increased follicle
numbers combined with follicular arrest. Several studies
showed that the increased serum AMH level in PCOS is
not only explained by the increased follicle number but
also by increased production per follicle compared to
normal ovaries [22,23]. In both follicular fluid and
isolated granulosa cells obtained after controlled ovarian
hyperstimulation for in vitro fertilization, AMH levels as
well as AMH and AMHR2 expression were increased in
samples from PCOS women compared to control women
[24,25]. Two additional studies in which the switch from
a gonadotropin-independent to gonadotropin-
dependent follicular stage was taken into account
confirmed these findings [26,27]. AMH expression and
follicular fluid AMH levels decline in gonadotropin-
dependent follicles in normoovulatory women, whereas
this did not occur in PCOS patients [26,27]. Likewise,
the coincided increase in E2 levels was absent in PCOS
patients [27]. This altered AMH expression may be the
result of intrinsic granulosa cell dysregulation in PCOS.
Both theca and granulosa cells of small antral follicles
express higher levels of the luteinizing hormone (LH)Current Opinion in Endocrine and Metabolic Research 2020, 12:91–97receptor in PCOS women compared to normoovulatory
women [28]. Combined with the elevated LH levels in
PCOS, this leads to hyperstimulation of the theca cells
and premature luteinization of granulosa cells. Inter-
estingly, LH stimulation increased AMH expression in
granulosa cells of PCOS women but not in normoovu-
latory women [24,29,30]. Treatment with 5-a-
dihydrotestosterone yielded similar results [30].
Furthermore, although estrogens suppress AMH
expression, mediated via estrogen receptor b, in
normoovulatory women, this suppression was not
observed in granulosa cells of anovulatory PCOS women
[30,31]. Combined, these results suggest a failure in the
downregulation of AMH expression in gonadotropin-
dependent follicular stages in PCOS, which may
contribute to a failure in follicular growth.
Interestingly, there may be another side of the AMH-
PCOS coin. Two recent studies from Gorsic et al.
[46,47] describe several PCOS-specific heterozygous
variants in the AMH and AMHR2 genes. In vitro studies
revealed that these variants significantly reduce AMH
signaling activity, through dominant negative effects
(AMH variants) and through splicing defects, reduced
expression, or reduced signaling (AMHR2 variants)
[46,47]. Based on the role of AMH in testicular Leydig
cells, the authors hypothesized that reduced AMH
signaling might lead to increased theca cell testosterone
(T) production because of loss of CYP17 inhibition.
However, reduced AMH bioactivity may also lead to less
inhibition of aromatase activity, thereby increasing the
conversion of T into E2. Thus, it remains to be deter-
mined how reduced AMH action affects follicular
growth and function.
Recently, studies have been performed in adult mice,
which may provide insight into the contribution of
elevated bioactive AMH in the PCOS pathophysiology
(summarized in Figure 1). Kano et al. and Pankhurst
et al. [32,33] both showed that treatment with supra-
physiological levels of AMH resulted in a phenotype
that resembles ovarian insufficiency rather than PCOS,
because a severe reduction in the number of growing
follicles from the primary follicle stage onwards was
observed. In the model of Hayes et al., daily AMH
treatment seemed to affect FSH sensitivity more
strongly than primordial follicle recruitment. In this
model, a significant reduction in antral follicle number
and number of corpora lutea was observed, along with an
increase in primordial, primary, and preantral follicle
number. However, in contrast to what is observed in
PCOS, LH receptor (LHCGR) and androgen receptor
(AR) expression were decreased. Unfortunately,
androgen levels were not reported for this model [34].
Overall, these studies suggest that exposure to strongly
elevated AMH levels during adulthood do not or only
partly induce PCOS characteristics, at least in awww.sciencedirect.com
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Summary of mouse models exposed to elevated AMH levels. (a) Refers to the model of Kano et al. (2017). (b) Refers to the model of Pankhurst et al.
(2018). (c) Refers to the model of Hayes et al. (2016). AMH levels in control fertile mice range between 28.34 ± 7.12 ng/ml measured with the DSL AMH
ELISA (DSL-10-14400). The figure was created with BioRender.com. AMH, anti-Müllerian hormone; AR, androgen receptor; FSH, follicle-stimulating
hormone; LH, luteinizing hormone; LHR, luteinizing hormone receptor; E2, estradiol; InhB, inhibin B.
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in these studies seem to override the effects on FSH
sensitivity as it already affects primordial follicle
recruitment. Recent studies, highlighting extragonadal
effects of AMH, strongly suggest that additional
mechanisms should be taken into account when
addressing a role of AMH in PCOS.AMH and its role in placental function in
PCOS
Recently, placental AMHR2 expression has been re-
ported in several species, including human [35e37].
Conflicting results exist regarding AMH expression
itself, because expression was detected in human but
not in bovine placenta [35,37]. Interestingly, although in
pregnant normoovulatory women, AMH levels decline
after the first trimester, in women with PCOS, AMH
levels remain significantly higher during pregnancy, but
only in lean PCOS women [36,38]. The presence of
elevated maternal AMH levels throughout pregnancy
and the existence of an AMH signaling pathway in thewww.sciencedirect.com Cuplacenta raises the question whether AMH affects
placental function in PCOS.
Tata et al. [36] showed that daily injection of AMH
during E16.5eE18.5 of pregnancy significantly
suppressed placental Cyp19a1 expression. Placental
aromatization is important to protect the fetus from
virilization by fetal androgens and to prevent the accu-
mulation of high androgen levels in the maternal circu-
lation [39]. Thus, elevated AMH may induce a
hyperandrogenic intrauterine environment, which re-
programs the reproductive axis of female offspring.
Indeed, increased T levels were measured in AMH-
treated pregnant mice and masculinization of the brain
was observed in the female offspring [36]. In agreement
with prenatal androgenized PCOS models, in
utero AMH-treated females displayed several reproduc-
tive PCOS-like phenotypes, including oligoanovulation,
altered gonadotropin-releasing hormone (GnRH)
pulsatility with elevated LH and T levels, whereas body
weight remained normal. In line with the oligoanovula-
tion, the number of large-antral follicles was reduced.rrent Opinion in Endocrine and Metabolic Research 2020, 12:91–97
Figure 2
Potential mechanisms of the contribution of AMH in the pathophysiology of PCOS. AMH may intervene at all three levels in the ovary–
placenta–brain crosstalk, thereby contributing to the etiology of PCOS. In the ovary, elevated AMH levels decrease Cyp19a1 expression in granulosa
cells, leading to increased T levels. Elevated LH levels increase AMH expression in granulosa cells and increase T production in the theca cells (dotted
arrow: transfer of T to granulosa cells). In the hypothalamus, exposure to increased AMH levels results in an increase in GnRH/LH pulsatility and
concentrations. In the pituitary, exposure to increased AMH levels results in increased FSH levels. Moreover, GnRH treatment may decrease AMHR2
expression in the pituitary, favoring LH over FSH production. In the placenta, increased maternal AMH decreases Cyp19a1 expression, preventing
aromatization of elevated maternal T levels, which in turn results in a hyperandrogenic intrauterine environment and masculinization of the fetus. The
figure was created with BioRender.com. 3bHSD1, 3-beta-hydroxysteroid-dehydrogenase-1; AMH, anti-Müllerian hormone; AMHR2, AMH-specific type II
receptor; E2, estradiol; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone; PCOS, polycystic ovary
syndrome; T, testosterone.
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the number of smaller growing follicles and AMH levels
itself was not reported. Importantly, the authors
demonstrated that AMH did not cross the placental
barrier, excluding a direct effect of AMH in the offspring
[36].
Interestingly, in women with PCOS, also a lower
placental Cyp19a1 expression has observed, accompa-
nied by increased placental 3-beta-hydroxysteroid-de-
hydrogenase-1 (3bHSD1) expression [40], which
potentially could contribute to a hyperandrogenic in-
trauterine environment. However, in the model of Tata
et al. [36], AMH treatment suppressed placental
3bHSD1 expression. It remains questionable whether
the placenta itself is solely responsible for the hyper-
androgenic intrauterine environment, because AMHCurrent Opinion in Endocrine and Metabolic Research 2020, 12:91–97treatment also resulted in elevated maternal LH levels,
which in turn could increase maternal T levels in these
mice. Indeed, combined treatment with a GnRH
antagonist prevented AMH-induced suppression of
Cyp19a1 and 3bHSD1 expression in the placenta and the
development of a PCOS-like phenotype in the female
offspring. These results suggest that AMH may also
have a central action.AMH and its role in brain function in PCOS
In addition to ovarian dysfunction, PCOS is also char-
acterized by neuroendocrine abnormalities, with
increased GnRH pulse frequency favoring LH over FSH
production. Recent studies suggest that AMH may also
play a role in the neuroendocrine dysregulation in PCOS
[36,41,42]. This hypothesis builds on the discovery of
AMHR2 expression in hypothalamic GnRH neurons inwww.sciencedirect.com
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responsive because AMH stimulated the excitability
and release of GnRH in neuronal explants of rats [42].
Furthermore, AMH injection directly into the lateral
ventricle of female mice induced a rapid increase in
GnRH-mediated LH pulsatility and secretion [42].
More support for a central action of AMH is provided by
additional studies from the same group [36,41]. In the
previously mentioned prenatal AMH-treated mouse
model, Tata et al. [36] observed increased LH concen-
tration and pulsation via induced GnRH neuronal ac-
tivity in the pregnant dams. Unfortunately, these
studies did not report whether AMH-stimulated GnRH
pulsatility also affected FSH levels. In PCOS patients,
AMH levels are positively correlated with LH concen-
trations [10]. High LH levels are known to stimulate
the release of ovarian androgen production by theca
cells, and as discussed earlier, LH enhances AMH
expression in granulosa cells of PCOS women. This
suggests the existence of a positive feedback loop be-
tween AMH, GnRH, and LH in PCOS.
In addition to hypothalamic function, AMH may also
regulate pituitary function given the presence of
AMHR2 expression, predominantly at prepubertal ages
[43e45]. In the LbT2 pituitary cell line, AMH stimu-
lated FSH secretion and FSHb expression, which was
confirmed in vivo in immature female rats 18 hours post-
AMH injection [44]. In contrast, in these studies, no
effect was observed on LH levels. In addition, it was
observed that pituitary AMHR2 expression was down-
regulated on continuous GnRH agonist treatment in
both mice and humans [44]. This may suggest that
increased GnRH release desensitizes the pituitary for
AMH, thereby contributing to LH over FSH produc-
tion. However, effects on AMHR2 expression may differ
depending on the rate of GnRH pulsatile release [43].
Given the stimulatory central actions of AMH, particu-
larly in the hypothalamus, it is remarkable that AMH
and AMHR2 heterozygous mutations leading to reduced
signaling (as discussed above) have been identified in a
subset of PCOS patients [46,47]. At the same time,
AMH and AMHR2 heterozygous loss-of-function muta-
tions were identified in patients with congenital hypo-
gonadotropic hypogonadism. Loss of AMHR2 signaling
in mice impairs GnRH neuronal migration resulting in
reduced LH levels at adult age [41]. The involvement
of AMH mutation in both PCOS and congenital hypo-
gonadotropic hypogonadism raises the question whether
these mutations display a different penetrance and
expressivity.Conclusion
AMH research in the scope of PCOS remains a very
intriguing topic. The recent studies highlighting extra-
gonadal functions of AMH indicate that thewww.sciencedirect.com Cucontribution of AMH to the pathophysiology of PCOS is
more complex than once thought. They suggest that
AMH may intervene at multiple levels of the braine
ovaryeplacenta crosstalk (Figure 2). Perhaps all three
tissues can contribute to the pathophysiology of PCOS
by establishing a vicious circle that reinforces itself
through an androgenegonadotrophin feedback loop.
However, it remains unclear whether ovarian AMH
expression is a driving force or an accomplice in this
crosstalk. As it has been shown now that AMH also has
extragonadal functions, this requires the need for tissue-
specific AMHR2 knockout models. Furthermore, the
identification of genetic AMH and AMHR2 mutations
suggests that AMH action not necessarily needs to be
increased to contribute to the PCOS pathophysiology,
implying that there may be different etiologies in
PCOS. Further studies into the mechanisms by which
AMH contributes to PCOS will help to understand this
heterogeneous disease.Funding
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